Literature DB >> 33434058

How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies.

Patrick M Reagan1, Sattva S Neelapu2.   

Abstract

Entities:  

Year:  2021        PMID： 33434058     DOI： 10.1200/JCO.20.01616

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Neurologic Complications of Cancer Therapies.

Authors:  Eudocia Q Lee
Journal:  Curr Neurol Neurosci Rep       Date:  2021-11-24       Impact factor: 5.081

Review 2.  Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.

Authors:  Praveen Ramakrishnan Geethakumari; Dheepthi Perumal Ramasamy; Bhagirathbhai Dholaria; Jesús Berdeja; Ankit Kansagra
Journal:  Curr Hematol Malig Rep       Date:  2021-06-05       Impact factor: 3.952

Review 3.  Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date.

Authors:  Hashim Mann; Raymond L Comenzo
Journal:  Onco Targets Ther       Date:  2022-07-22       Impact factor: 4.345

Review 4.  Cardiovascular disease and chimeric antigen receptor cellular therapy.

Authors:  Anjali Rao; Andrew Stewart; Mahmoud Eljalby; Praveen Ramakrishnan; Larry D Anderson; Farrukh T Awan; Alvin Chandra; Srilakshmi Vallabhaneni; Kathleen Zhang; Vlad G Zaha
Journal:  Front Cardiovasc Med       Date:  2022-09-23

Review 5.  DLBCL 1L-What to Expect beyond R-CHOP?

Authors:  Maike Stegemann; Sophy Denker; Clemens A Schmitt
Journal:  Cancers (Basel)       Date:  2022-03-11       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.